Showing results (221-230 of 722) with videos related to
Sort By:
Pageof 73
The Lancet. Haematology|May 20, 2017
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalanYago Nieto, Benigno C Valdez, Sai R Pingali, et al.The Lancet. Haematology|June 7, 2017
Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trialJürgen Finke, Claudia Schmoor, Wolfgang Andreas Bethge, et al.The Lancet. Haematology|June 2, 2017
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trialRichard E Clark, Fotios Polydoros, Jane F Apperley, et al.The Lancet. Haematology|May 2, 2017
Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trialPetra Innerhofer, Dietmar Fries, Markus Mittermayr, et al.The Lancet. Haematology|July 3, 2017
Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional studyAndy C Rawstron, Aloysius Ssemaganda, Ruth de Tute, et al.The Lancet. Haematology|July 4, 2017
Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trialJules A A C Heuberger, Joris I Rotmans, Pim Gal, et al.The Lancet. Haematology|November 29, 2016
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trialJorge E Cortes, Carmino Antonio De Souza, Manuel Ayala, et al.The Lancet. Haematology|August 8, 2020
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 studyJean-Marie Michot, Reda Bouabdallah, Umberto Vitolo, et al.The Lancet. Haematology|April 15, 2023
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countriesFrance Pirenne, Aline Floch, Saliou DiopThe Lancet. Haematology|April 1, 2023
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the pastNicholas J Short, Hagop KantarjianPageof 73